Plants have long been recognized as valuable sources of medicine, with numerous herbal drugs derived from plant compounds. Plumbago zeylanica Linn., a member of the Plumbaginaceae family, is a perennial sub scandent shrub widely used in traditional Indian medicine. The study aims to explore the potential of various parts of Plumbago zeylanica in the treatment of diabetic nephropathy by investigating in-vitro experiments and conducting molecular docking studies with proteins associated with the disease. The in-vitro findings exhibited that the extract of roots have greater inhibition activity than stem extract, followed by the leaf extracts of Plumbago zeylanica. The glucose uptake assay showed that the enhancement of glucose transport was different for all three concentrations of glucose solution. In molecular docking, the highest binding affinities of Plumbago zeylanica bioactive compounds and target proteins were ranging from -7.196 to -9.447. Additionally, the lowest binding affinities of Plumbago zeylanica bioactive compounds and target proteins were ranging from -3.779 to -7.196, which were also higher than reference compound for different active constituents. ADMET prediction was performed to assess the pharmacokinetic properties of the active constituents. The findings of this study will shed light on the phytochemical composition of Plumbago zeylanica and its potential as a therapeutic agent for diabetic nephropathy.